Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.44 |
| ▸ | NEK2 | P51955 | 6/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320440 | 0.83 | NEK2 (0.45) | NEK2PIK3CAMTORPLK1NEK1 | |
| SCHEMBL2321276 | 0.78 | ROCK2 (0.67) | NEK2PLK1NEK1ROCK2ROCK1 | |
| SCHEMBL22234855 | 0.77 | MAPT (0.49) | NEK2ROCK2ROCK1 | |
| SCHEMBL2325112 | 0.77 | PTPN11 (0.44) | NEK2PLK1NEK1 | |
| SCHEMBL28072187 | 0.76 | HTR2C (0.50) | — | |
| SCHEMBL2317513 | 0.76 | CYP1A2 (0.47) | ROCK2ROCK1 | |
| SCHEMBL1445139 | 0.73 | KDM4E (0.51) | PIK3CAMTORPIK3R1 | |
| SCHEMBL3146942 | 0.73 | HRH4 (0.54) | ROCK2ROCK1 | |
| SCHEMBL30366458 | 0.73 | KDM4E (0.51) | PIK3CAMTORPIK3R1 | |
| SCHEMBL17700131 | 0.72 | ABL1 (0.52) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1830853-B1 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2011-08-10 | — | — | EP | disclosed |
| CN-101102773-B | Aminopyrazine analogs for the treatment of glaucoma and other RHO kinase-mediated diseases | ALCON INC | 2010-10-27 | — | — | CN | disclosed |
| US-20080269249-A2 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON, INC. (CH) | 2008-10-30 | — | — | US | disclosed |
| CN-101102773-A | Aminopyrazine analogs for the treatment of glaucoma and other RHO kinase-mediated diseases | ALCON INC (CH) | 2008-01-09 | — | — | CN | disclosed |
| EP-1830853-A2 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES | ALCON INC. (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006071548-A2 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES | ALCON, INC. (CH) | 2006-07-06 | — | — | WO | disclosed |
| US-20060142307-A1 | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | ALCON, INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269249-A2 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK2, ROCK1, RHOA | PDE10A 278/4885NEK2 481/4885PIK3CA 1124/4885 |
| US-20060142307-A1 | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | ROCK2, ROCK1, RHOA | PDE10A 278/4885NEK2 481/4885PIK3CA 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.